Key Points
-
A method of placing patients into a risk category for bisphosphonate osteonecrosis of the jaws following a tooth extraction is proposed.
-
This information can be used in the informed consent process prior to a planned tooth extraction.
-
A management protocol is described in relation to each risk category in particular when to use adjuvants to treatment such as surgical antibiotic prophylaxis.
Abstract
Bisphosphonate-associated osteonecrosis of the jaws (BONJ) is recognised as a significant complication related to the use of bisphosphonates and currently is gaining importance due to the increasingly widespread use of these medications. Patients are placed into low or high risk groups of developing BONJ depending on the systemic condition for which they have received bisphosphonates. Numerically, the largest group worldwide is patients receiving bisphosphonates for osteoporosis and these generally fall into the low risk group for BONJ. The high risk group, while numerically smaller, is composed of those patients receiving bisphosphonates in the management of malignancy affecting the skeleton, either primary or secondary (metastatic disease). A number of additional systemic and local risk factors are proposed, which have the effect of increasing the risk of BONJ following an extraction. These risk factors may have the effect of moving a low risk categorised patient into a medium, or perhaps more realistically an unknown risk category. An example of a systemic risk factor is the concurrent use of corticosteroids and a local risk factor is mandibular molar extraction. The purpose of this paper is to define and validate an algorithm to guide clinicians in the area of patient information, consent and management for patients currently taking or having previously taken bisphosphonates who require dental extractions.
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Zahrowski J J. Comment on the American Association of Oral and Maxillofacial Surgeons statement on bisphosphonates. J Oral Maxillofac Surg 2007; 65: 1440–1441.
Sarin J, DeRossi S S, Akintoye S O. Updates on bisphosphonates and potential pathobiology of bisphosphonate-induced jaw osteonecrosis. Oral Dis 2008; 14: 277–285.
Wood J, Bonjean K, Ruetz S et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 2002; 302: 1055–1061.
Reid I R, Bolland M J, Grey A B. Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity? Bone 2007; 41: 318–320.
Marx R E, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005; 63: 1567–1575.
Dimopoulos M A, Kastritis E, Anagnostopoulos A et al. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid. Haematologica 2006; 91: 968–971.
Advisory Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2007; 65: 369–376.
Khosla S, Burr D, Cauley J et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007; 22: 1479–1491.
American Dental Association Council on Scientific Affairs. Dental management of patients receiving oral bisphosphonate therapy: expert panel recommendations. J Am Dent Assoc 2006; 137: 1144–1150.
Coleman R E. Emerging strategies in bone health management for the adjuvant patient. Semin Oncol 2007; 34(6 Suppl 4): S11–S16.
Assouline-Dayan Y, Chang C, Greenspan A et al. Pathogenesis and natural history of osteonecrosis. Semin Arthritis Rheum 2002; 32: 94–124.
Corticosteroid-induced osteoporosis. In British National Formulary 54. Section 6.6:401. London: BMJ Publishing Group Ltd, 2007.
Patschan D, Loddenkemper K, Buttgereit F. Molecular mechanisms of glucocorticoid-induced osteoporosis Bone 2001; 29: 498–505.
Merck Sharp & Dohme Ltd. Fosamax. Section 5.2: pharmacokinetic properties. In Electronic Medicines Compendium. Available at http://www.emc.medicines.org.uk.
Silverman S L, Maricic M. Recent developments in bisphosphonate therapy. Semin Arthritis Rheum 2007; 37: 1–12.
Meechan J G, Macgregor I D, Rogers S N et al. The effect of smoking on immediate post-extraction socket filling with blood and on the incidence of painful socket. Br J Oral Maxillofac Surg 1988; 26: 402–409.
Bergstrom J. Periodontitis and smoking: an evidence-based appraisal. J Evid Based Dent Pract 2006; 6: 33–41.
Jorgensen L N, Kalehave F, Christensen E et al. Less collagen production in smokers. Surgery 1998; 123: 450–455.
Iwaniec U T, Fung Y K, Akhter M P et al. Effects of nicotine on bone mass, turnover and strength in adult female rats. Calcif Tissue Int 2001; 68: 358–364.
Pazianas M, Miller P, Blumentals W A et al. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. Clin Ther 2007; 29: 1548–1558.
British National Formulary for children. Section 6.6.2: Bisphosphonates. pp 455–457. London: BMJ Publishing Group Ltd, 2007.
Black D M, Schwartz A V, Ensrud K E et al. Effects of continuing or stopping alendronate after 5 years of treatment. The fracture intervention trial long-term extension (FLEX): a randomized trial. JAMA 2006; 296: 2927–2938.
Glick M. Closing in on the puzzle of ONJ. J Am Dent Assoc 2008; 139: 12–15.
Mavrokokki T, Cheng A, Stein B, Goss A. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 2007; 65: 415–423.
Grbic J T, Landesberg R, Lin S Q et al. Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial. J Am Dent Assoc 2008; 139: 32–40.
Hermesch C B, Hilton T J, Biesbrock A R et al. Perioperative use of 0.12% chlorhexidine gluconate for the prevention of alveolar osteitis: efficacy and risk factor analysis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1998; 85: 381–387.
Scottish Intercollegiate Guidelines Network. Antibiotic prophylaxis in surgery. Edinburgh: SIGN, 2000. Guideline 45.
Marx E. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 2007; 65: 2397–2410.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Malden, N., Beltes, C. & Lopes, V. Dental extractions and bisphosphonates: the assessment, consent and management, a proposed algorithm. Br Dent J 206, 93–98 (2009). https://doi.org/10.1038/sj.bdj.2009.5
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sj.bdj.2009.5
This article is cited by
-
Comment on: A multicenter retrospective study of the risk factors associated with medication-related osteonecrosis of the jaw after tooth extraction in patients receiving oral bisphosphonate therapy: can primary wound closure and a drug holiday really prevent MRONJ?
Osteoporosis International (2023)
-
A student guide to MRONJ
BDJ Student (2022)
-
Tooth extraction in mice administered zoledronate increases inflammatory cytokine levels and promotes osteonecrosis of the jaw
Journal of Bone and Mineral Metabolism (2021)
-
Low-dose methotrexate in rheumatoid arthritis: a potential risk factor for bisphosphonate-induced osteonecrosis of the jaw
Oral and Maxillofacial Surgery (2018)
-
A multicenter retrospective study of the risk factors associated with medication-related osteonecrosis of the jaw after tooth extraction in patients receiving oral bisphosphonate therapy: can primary wound closure and a drug holiday really prevent MRONJ?
Osteoporosis International (2017)
